United States Patent 9,072,742: Iloperidone Pharmacogenomic Patent Scope, Expiration, Litigation and Generic Risk
U.S. Patent No. 9,072,742 protects a genotype-guided method for administering iloperidone or a specified iloperidone metabolite. The core marker is the BAI3 gene single-nucleotide polymorphism rs1083338. Patients with the GG genotype receive a lower quantity; patients with any non-GG genotype receive a higher quantity. The patent also covers administration to patients with long QT syndrome and dependent claims involving CYP2D6 testing and a 24 mg/day dose.
The patent is a method-of-treatment patent, not a composition, formulation or manufacturing patent. Its commercial relevance depends on whether physicians, treatment protocols, diagnostic services or generic labeling direct use of iloperidone according to the claimed BAI3 genotype rule.
What patents protect iloperidone and Fanapt?
Iloperidone, marketed in the United States as Fanapt, is an atypical antipsychotic approved for schizophrenia. The product is associated with Vanda Pharmaceuticals Inc. and was originally developed under the development code iloperidone or HP-873.
U.S. Patent 9,072,742 covers a pharmacogenomic dosing method rather than the iloperidone molecule itself.
| Patent |
Subject matter relevant to iloperidone |
Patent type |
Strategic significance |
| U.S. 9,072,742 |
BAI3 rs1083338 genotype-guided iloperidone dosing |
Method of treatment |
Controls a specific pharmacogenomic dosing protocol |
| U.S. 8,586,610 |
Iloperidone treatment based principally on CYP2D6 metabolism and dose adjustment |
Method of treatment |
Addresses metabolizer status and dose selection |
| U.S. 5,364,866 |
Iloperidone compound and related pharmaceutical subject matter |
Compound and pharmaceutical patent |
Historic foundational protection |
| FDA Fanapt labeling |
Dose titration, CYP2D6 poor-metabolizer adjustment and QT-risk warnings |
Regulatory labeling |
Relevant to inducement and generic-labeling disputes |
The scope of U.S. 9,072,742 is narrower than a compound patent. It does not prevent every use, sale or manufacture of iloperidone. It targets a particular clinical decision process.
What are the independent claims of U.S. Patent 9,072,742?
Claims 1 and 5 are the two independent claims.
Claim 1: genotype-guided administration
Claim 1 requires all of the following:
- A human individual.
- Administration of iloperidone or an iloperidone metabolite.
- Determination, or prior determination, of the individual’s BAI3 gene sequence at rs1083338.
- Administration of a lower first quantity when the genotype is GG.
- Administration of a higher second quantity when the genotype is non-GG.
The phrase “non-GG” covers the remaining genotype categories, including AG and AA, assuming the relevant allele representation is the conventional two-allele genotype notation.
The claim is therefore a conditional dosing algorithm:
| BAI3 rs1083338 genotype |
Claimed treatment |
| GG |
Lower quantity |
| AG or other non-GG genotype |
Higher quantity |
The claim does not specify an absolute lower dose in independent claim 1. It requires only that the quantity administered to a GG patient be lower than the quantity administered to a non-GG patient.
Claim 5: treatment of a patient with long QT syndrome
Claim 5 adds a disease-state limitation. It requires:
- A human individual suffering from long QT syndrome;
- Administration of iloperidone or the specified metabolite;
- BAI3 rs1083338 genotype determination;
- A lower quantity for a GG patient;
- A higher quantity for a non-GG patient.
This claim is narrower than claim 1 because it requires LQTS. It is also commercially unusual because iloperidone labeling warns about QT prolongation and advises against use in patients with known arrhythmias or prolonged QT intervals.[2]
The LQTS limitation may create a substantial infringement and validity issue. A defendant could argue that the claimed treatment conflicts with the product’s safety labeling or lacks a credible therapeutic rationale for the identified patient population. Those arguments would depend on the patent specification, prosecution history, clinical evidence and the asserted claim construction.
What do the dependent claims add?
Claims 2, 4, 6, 8, 9 and 10 add specific limitations.
| Claim |
Added limitation |
| 2 |
Determining the patient’s CYP2D6 genotype under claim 1 |
| 3 |
The compound is iloperidone |
| 4 |
The compound is the specified iloperidone metabolite |
| 6 |
Determining CYP2D6 genotype under claim 5 |
| 7 |
The compound is iloperidone |
| 8 |
The compound is the specified metabolite |
| 9 |
The higher iloperidone quantity is 24 mg/day |
| 10 |
The higher iloperidone quantity is 24 mg/day under the LQTS claim |
The specified metabolite is:
1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]ethanol.
Claims 9 and 10 create the clearest dose-specific infringement scenario. They require the non-GG patient to receive 24 mg/day. They do not expressly define the lower quantity administered to GG patients beyond the requirement that it be lower.
How strong is the patent estate for U.S. Patent 9,072,742?
The patent has meaningful claim differentiation but a narrow practical perimeter.
Strengths
The patent has several features that can support enforcement:
- It identifies a precise genomic locus rather than a broad disease-response concept.
- It links genotype to a concrete dosing distinction.
- It covers both iloperidone and a named metabolite.
- It includes a 24 mg/day dependent claim.
- It can potentially reach treatment protocols in which genotype information is obtained by a third-party laboratory.
- “Determining or having determined” is drafted to cover situations in which the treating physician relies on a test performed by another entity.
Weaknesses
The principal limitations are equally important:
- The claims require knowledge or determination of the BAI3 genotype.
- The claims require different quantities for GG and non-GG patients.
- A prescription or label that merely permits a range of doses may not practice the claimed genotype-dependent rule.
- The claims do not cover ordinary iloperidone treatment without BAI3 testing.
- The LQTS claims face clinical and regulatory tension because iloperidone can prolong QT.
- The patent does not cover the manufacture of iloperidone or a generic tablet as such.
- The claims may be vulnerable to written-description, enablement, anticipation or obviousness arguments depending on the patent record and prior art.
The patent’s practical strength is therefore highest where a product label, electronic medical record, clinical protocol or laboratory report explicitly instructs the prescriber to use the BAI3 rs1083338 genotype to choose between lower and higher doses.
When does U.S. Patent 9,072,742 expire?
The patent has an earliest claimed priority date in September 2008. Applying the standard 20-year term measured from the earliest effective nonprovisional filing date, the expected nominal expiration is in September 2029, subject to patent-term adjustment, terminal disclaimers and any applicable statutory correction.
| Event |
Date or period |
| Earliest priority period |
September 2008 |
| Patent grant |
July 7, 2015 |
| Expected nominal patent expiration |
September 2029 |
| Patent type |
Utility method-of-treatment patent |
The exact enforceable expiration date must be taken from the USPTO patent-term calculation and the patent’s face record. Patent expiration does not itself establish FDA exclusivity or guarantee that all listed claims remain enforceable.
What is the Orange Book status of U.S. Patent 9,072,742?
A method-of-use patent may be listed in the FDA Orange Book if it claims an approved method of using the drug. If listed against the Fanapt NDA, it can require an ANDA applicant to address the patent through a Paragraph IV certification or a statement that the applicant will not market the product for the patented use.
The regulatory significance depends on three questions:
- Whether U.S. Patent 9,072,742 is listed against NDA 022264.
- Whether the listing carries an FDA use code corresponding to genotype-guided iloperidone dosing.
- Whether the ANDA applicant seeks approval for the patented method or uses a permissible carve-out.
The patent does not create a block against every generic iloperidone product. A generic applicant may pursue a section viii labeling carve-out if the patented method can be omitted from the proposed labeling and the remaining approved uses are not dependent on that method. That strategy becomes more difficult if the reference labeling expressly instructs BAI3 testing or if the generic label promotes the genotype-guided dose selection.
FDA-approved Fanapt labeling identifies dose titration and CYP2D6-related dose considerations. It also identifies QT prolongation as a safety concern and provides a maximum recommended daily dose of 24 mg for many patients.[2]
What Paragraph IV challenges and litigation affect Fanapt?
Vanda has litigated Fanapt method-of-use patents against generic applicants, including Teva. The most important precedent is Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., which addressed induced infringement and obviousness issues involving a Vanda iloperidone dosing patent.[3]
The litigation matters to U.S. Patent 9,072,742 because it establishes the commercial importance of method-of-treatment patents in the Fanapt franchise. The central enforcement question is whether a generic applicant’s proposed label and expected physician use cause the patented dosing method to be performed.
A Paragraph IV case involving this patent would likely focus on:
- Whether the ANDA label instructs or encourages BAI3 genotype testing.
- Whether the label directs a lower dose for GG patients and a higher dose for non-GG patients.
- Whether physicians are likely to perform the claimed steps.
- Whether laboratory testing by another entity satisfies “determining or having determined.”
- Whether the genotype-dose relationship was adequately supported by the specification.
- Whether the claimed dosing rule was obvious in view of pharmacogenomic and QT-risk literature.
The Federal Circuit’s treatment of induced infringement in the Fanapt litigation makes the proposed labeling central. A generic applicant does not necessarily avoid risk merely by omitting an explicit instruction if the remaining label materially encourages the patented use. Conversely, a carefully drafted carve-out may reduce risk where noninfringing uses remain commercially meaningful.[3]
No settlement term should be assumed from the existence of litigation. A settlement could include a license, an agreed launch date, a label carve-out, or a covenant relating to particular claims. Those terms are commercially material but must be confirmed from the specific case docket or settlement filing.
Does U.S. Patent 9,072,742 create biosimilar risk?
No conventional biosimilar risk exists. Iloperidone is a small-molecule drug regulated through the ANDA pathway, not a biologic regulated under the section 351(k) biosimilar pathway.
The relevant competitive threat is generic substitution. The principal regulatory mechanisms are:
- ANDA filing;
- Paragraph IV certification;
- section viii use carve-out;
- 30-month stay where statutory conditions are met;
- patent litigation under Hatch-Waxman;
- possible pediatric or other exclusivity periods associated with the NDA.
What formulation and manufacturing patents protect iloperidone?
U.S. Patent 9,072,742 does not claim:
- A tablet formulation;
- A specific excipient system;
- A sustained-release or depot formulation;
- A manufacturing process;
- A crystalline or polymorphic form;
- A composition containing iloperidone at a defined strength.
Those rights, if any, must be found in separate patent families. The patent’s manufacturing barrier is therefore low. A generic manufacturer can generally make an equivalent iloperidone product without practicing the claimed BAI3 dosing method, provided its commercial activities do not induce the patented use.
The main technical barriers are clinical and regulatory rather than manufacturing-based:
- validated BAI3 testing;
- integration of genetic results into prescribing systems;
- physician adoption;
- evidence supporting genotype-based dose selection;
- management of QT-prolongation risk;
- avoidance of label language that encourages the patented method.
How does U.S. Patent 9,072,742 compare with CYP2D6-based iloperidone patents?
The BAI3 patent and CYP2D6-related patent claims address different biological variables.
| Issue |
BAI3 patent |
CYP2D6-related protection |
| Genetic factor |
BAI3 rs1083338 |
CYP2D6 metabolizer genotype |
| Core use |
GG patients receive less; non-GG patients receive more |
Dose adjustment based on metabolism status |
| Dose expressly recited |
24 mg/day in claims 9 and 10 |
Depends on the relevant patent claims and label |
| Clinical relationship |
Pharmacogenomic response or risk stratification |
Drug metabolism and exposure |
| Commercial overlap |
Same iloperidone treatment setting |
Same iloperidone treatment setting |
| Infringement trigger |
BAI3 testing plus genotype-directed dose selection |
CYP2D6 testing or metabolizer-directed dose selection |
A physician could practice one method, both methods, or neither. Claims 2 and 6 expressly add CYP2D6 testing to the BAI3-based regimen, creating a combination claim that may be harder to practice but narrower in scope.
What generic launch scenarios exist?
Scenario 1: Generic launch with no pharmacogenomic instruction
This is the lowest direct risk scenario for U.S. Patent 9,072,742. The generic label would provide approved iloperidone dosing without instructing clinicians to test BAI3 rs1083338 or select a dose based on GG versus non-GG status.
Scenario 2: Section viii carve-out
A generic applicant may attempt to omit the patented genotype-guided use while retaining ordinary schizophrenia treatment. The commercial value of this strategy depends on whether the carved-out use is separable from the remaining label and whether the proposed label indirectly encourages the patented method.
Scenario 3: Label containing BAI3 dosing instructions
This is the highest litigation risk. A label that identifies rs1083338, distinguishes GG from non-GG patients and directs different quantities could satisfy every material limitation of claims 1 and 9.
Scenario 4: Post-expiration launch
A generic could launch broadly after expiration, subject to other unexpired patents, regulatory exclusivities, injunctions and product-specific litigation outcomes.
What is the commercial exposure from this patent?
U.S. Patent 9,072,742 protects a narrow use within the larger Fanapt business. Its economic value is not equal to total iloperidone sales because ordinary, non-genotype-guided prescriptions may fall outside the claims.
The patent can still have strategic value in three areas:
- delaying an unrestricted generic label;
- increasing settlement leverage in ANDA litigation;
- preserving a differentiated pharmacogenomic use for Fanapt.
Revenue exposure is therefore driven by the share of prescriptions that would use BAI3 testing and genotype-directed dosing, not by all Fanapt prescriptions. Public company filings report Fanapt product sales at the franchise level, but they do not generally allocate revenue specifically to the rs1083338 patented method.[4]
Key Takeaways
- U.S. Patent 9,072,742 is a method-of-treatment patent owned in the Vanda iloperidone patent estate.
- Its core limitation is BAI3 rs1083338 testing followed by a lower dose for GG patients and a higher dose for non-GG patients.
- Claims 9 and 10 specifically identify 24 mg/day as the higher iloperidone dose.
- Claims 5 through 10 extend the method to patients with long QT syndrome, creating a narrower but clinically controversial claim set.
- The patent does not protect iloperidone as a compound, tablet formulation or manufacturing process.
- The expected nominal expiration is in September 2029, subject to the official patent-term calculation.
- Generic risk depends heavily on labeling, physician instruction and whether a section viii carve-out can remove the patented use.
- Iloperidone is a small molecule, so generic ANDA competition, not biosimilar competition, is the relevant threat.
- The strongest infringement case would involve a label or clinical protocol expressly directing BAI3 testing and genotype-specific dose selection.
FAQs
Can a generic sell iloperidone without infringing U.S. Patent 9,072,742?
Yes, potentially. The patent does not cover every sale of iloperidone. Risk increases if the generic label instructs BAI3 testing and genotype-dependent dose selection.
Does testing BAI3 alone infringe the patent?
No. The claims require both genotype determination and administration of different iloperidone quantities based on GG versus non-GG status.
Is the 24 mg/day dose independently protected?
Claims 9 and 10 specifically recite 24 mg/day as the higher quantity for non-GG patients. The dose limitation applies only in combination with the other limitations of the underlying claims.
Can a physician infringe the LQTS claims by following the Fanapt label?
The answer depends on the actual treatment facts, the claim construction and whether the patient has LQTS as claimed. The conflict between the LQTS claims and QT-prolongation warnings would be central to any dispute.
Does CYP2D6 testing replace BAI3 testing under the patent?
No. Claims 2 and 6 add CYP2D6 genotype determination to the BAI3 method. CYP2D6 testing alone does not satisfy the BAI3 rs1083338 limitation.
References
- United States Patent and Trademark Office. (2015). U.S. Patent No. 9,072,742, Methods of treating patients with iloperidone.
- U.S. Food and Drug Administration. (2024). Fanapt (iloperidone) prescribing information.
- Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., 61 F.4th 136 (Fed. Cir. 2023).
- Vanda Pharmaceuticals Inc. (2024). Form 10-K annual report. U.S. Securities and Exchange Commission.
